Skip header and navigation

3 records – page 1 of 1.

Danish Breast Cancer Cooperative Group--DBCG: History, organization, and status of scientific achievements at 30-year anniversary.

https://arctichealth.org/en/permalink/ahliterature93219
Source
Acta Oncol. 2008;47(4):497-505
Publication Type
Article
Date
2008
Author
Blichert-Toft Mogens
Christiansen Peer
Mouridsen Henning T
Author Affiliation
The Danish Breast Cancer Cooperative Group, DBCG Secretariat, Rigshospitalet, Copenhagen.
Source
Acta Oncol. 2008;47(4):497-505
Date
2008
Language
English
Publication Type
Article
Keywords
Anniversaries and Special Events
Breast Neoplasms - history - therapy
Denmark
Female
History, 20th Century
History, 21st Century
Humans
Medical Oncology - history - organization & administration
Societies, Medical - history - organization & administration
Abstract
DBCG (Danish Breast Cancer Cooperative Group) constitutes a multidisciplinary organization established in 1975 by the Danish Surgical Society. The purpose involves first and foremost a nation-wide standardization of breast cancer treatment based on novel therapeutic principles, collaboration between experts handling diagnostic work-up, surgery, radiotherapy, medical oncology, and basic research, and, further, complete registration of relevant clinical data in a national data base attached to DBCG. Data are processed by the Secretariat personnel composed of statisticians, data managers, and data secretaries making current analyses of outcome results feasible. DBCG is run by the Executive Committee consisting of expert members appointed by their respective society. From 1978 the DBCG project gained widely accession from participating units, and since then nearly all newly diagnosed breast cancer incident cases are reported and registered in the national data base. Today, the data base includes approximately 80 000 incidents of primary breast cancer. Annually, the Secretariat receives roughly 1.5 million parameters to be entered into the data base. Over time DBCG has generated seven treatment programmes including in situ lesions and primary invasive breast cancer. Probands are subdivided into risk groups based on a given risk pattern and allocated to various treatment programmes accordingly. The scientific initiatives are conducted in the form of register- and cohort analysis or randomized trials in national or international protocolized settings. Yearly, about 4 000 new incident cases of primary invasive breast cancer and about 200 in situ lesions enter the national programmes. Further, about 600 women with hereditary disposition of breast cancer are registered and evaluated on a risk scale. The main achievements resulted in a reduction of relative risk of death amounting up to 20% and increased 5-year overall survival ascending from 60% to roughly 80%. This article is partly based on a Danish paper to be published in the Centenary Jubilee book of the Danish Surgical Society, 2008.
PubMed ID
18465316 View in PubMed
Less detail

Improvement of prognosis in breast cancer in Denmark 1977-2006, based on the nationwide reporting to the DBCG Registry.

https://arctichealth.org/en/permalink/ahliterature93218
Source
Acta Oncol. 2008;47(4):525-36
Publication Type
Article
Date
2008
Author
Mouridsen Henning T
Bjerre Karsten D
Christiansen Peer
Jensen Maj-Britt
Møller Susanne
Author Affiliation
DBCG Registry, Copenhagen, Denmark.
Source
Acta Oncol. 2008;47(4):525-36
Date
2008
Language
English
Publication Type
Article
Keywords
Aged
Breast Neoplasms - epidemiology - mortality - pathology - therapy
Combined Modality Therapy
Denmark - epidemiology
Disease-Free Survival
Female
Humans
Lymphatic Metastasis
Middle Aged
Registries
Risk factors
Treatment Outcome
Abstract
INTRODUCTION: Since 30 years DBCG (Danish Breast Cancer Coperative Group) has maintained, on a nation-wide basis, a clinical database of diagnostic procedures, therapeutic interventions, and clinical outcome in patients with primary breast cancer. The present analysis was undertaken to evaluate the development of the prognosis since 1977, and to analyse factors potentially contributing to the change of the prognosis. MATERIAL AND METHODS: All cases of invasive breast cancer reported to DBCG during the period 1977-2006 were included in the present analysis. RESULTS: A total of close to 80 000 patients were registered in the DBCG Database. Since 1977 the prognosis has improved significantly, thus 5 year survival for the total population of patients with primary breast cancer has increased from 65 to 81%. DISCUSSION: According to the present analysis diagnosis at an earlier stage in the natural course of the disease and especially the development of more active systemic treatment modalities have contributed to the improved prognosis.
PubMed ID
18465318 View in PubMed
Less detail

Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer.

https://arctichealth.org/en/permalink/ahliterature89041
Source
J Natl Cancer Inst. 2009 May 20;101(10):729-35
Publication Type
Article
Date
May-20-2009
Author
Ejlertsen Bent
Jensen Maj-Britt
Rank Fritz
Rasmussen Birgitte B
Christiansen Peer
Kroman Niels
Kvistgaard Marianne E
Overgaard Marie
Toftdahl Dorte B
Mouridsen Henning T
Author Affiliation
Department of Oncology, Bldg 4262 Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. ejlertsen@rh.dk
Source
J Natl Cancer Inst. 2009 May 20;101(10):729-35
Date
May-20-2009
Language
English
Publication Type
Article
Keywords
Adult
Aged
Breast Neoplasms - pathology - surgery - therapy
Denmark
Disease-Free Survival
Female
Follow-Up Studies
Humans
Lymphatic Metastasis
Middle Aged
Neoplasm Invasiveness
Prognosis
Reproducibility of Results
Risk
Treatment Outcome
Abstract
BACKGROUND: Lymphovascular invasion has been associated with poor prognosis in women with breast cancer, but it is unclear whether the presence of lymphovascular invasion should be considered sufficient to reclassify breast cancer patients who are at a low risk of recurrence into a high-risk category. METHODS: Of the 16,172 patients with operable breast cancer who were entered into the Danish Breast Cancer Cooperative Group Registry from January 1, 1996, to December 31, 2002, lymphovascular invasion was classified at primary diagnosis in 16,121 patients as present (n = 2453, 15%) or as absent (n = 13,206, 82%). Patients with at least one of the risk criteria (positive lymph nodes, tumor size > 2 cm, high grade, hormone receptor-negative tumor, or younger than 35 years) were assigned to the high-risk group; the other patients were assigned to the low-risk group. All procedures, including report forms, central review, and querying, were specified in advance. Kaplan-Meier analyses were used to estimate disease-free intervals and overall survival rates among patients with and without lymphovascular invasion, and multivariable analysis was used to adjust for differences in baseline characteristics and therapy. All statistical tests were two-sided. RESULTS: Complete follow-up was achieved for 15,659 patients. The median estimated potential follow-up was 6.4 years for invasive disease-free interval and 7.7 years for overall survival. Invasive disease-free interval and overall survival were statistically significantly associated with lymphovascular invasion within the high-risk group (hazard ratio [HR] for invasive disease = 2.29, 95% confidence interval [CI] = 2.14 to 2.45, P
Notes
Comment In: J Natl Cancer Inst. 2009 May 20;101(10):698-919436037
PubMed ID
19436035 View in PubMed
Less detail